You just read:

Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimer's Disease

News provided by

Neurotrope, Inc.

Nov 22, 2016, 09:12 ET